阿姆莱克萨诺克斯对TBK1的向抑制调节免疫细胞功能,加剧DSS诱导的炎症性肠病
Lu Hui1, Meng-Ke Huang1, Qing-Kai Dai1
1Department of Laboratory Medicine, West China Second University Hospital, and Key Laboratory of Obstetric & Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, Sichuan University, Chengdu, China.
Clinical and experimental immunology
|September 9, 2024
概括
阿姆莱克萨诺克斯 (ALX) 通过促进亲炎性T细胞反应,在小鼠中加剧了结肠炎,尽管抑制了TBK1. 这表明单单针对TBK1是治疗炎症性肠病 (IBD) 的不足.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 胃肠病学 胃肠病学
背景情况:
- 阿姆莱克萨诺克斯 (Amlexanox,简称ALX) 是一种治疗炎症和自身免疫性疾病的药物.
- 它对炎症性肠病 (IBD) 的治疗效果尚未研究.
- 目前正在调查TBK1在结肠炎发病过程中的作用.
研究的目的:
- 在小鼠模型中研究Amlexanox (ALX) 对硫酸诱导的大肠炎的影响.
- 探索ALX向抑制结肠炎中的TBK1的机制.
- 评估ALX作为IBD治疗剂的潜力.
主要方法:
- 德克斯硫酸 (DSS) 诱导的大肠炎小鼠模型.
- 艾姆莱克萨诺克斯 (ALX) 的使用和结肠炎严重程度和生存率的评估.
- 通过ELISA和流细胞测量来分析细胞因子概况和免疫细胞群.
- 药物安全实验,以排除毒性.
主要成果:
- 艾姆莱克萨诺克斯 (ALX) 在小鼠中加剧了结肠炎和降低了生存率,独立于药物毒性.
- ALX抑制了TBK1-NF-κB和TBK1-IRF3通路,但促进了IL-1β和IFN-α的分泌.
- ALX促进了T细胞的激活和分化,同时抑制了树突细胞的产生和M1巨细胞的两极化,表明了双向免疫效应.
结论:
- 通过Amlexanox (ALX) 制TBK1的向抑制对治疗结肠炎没有效果.
- ALX对免疫细胞表现出双向作用,对T细胞具有促炎作用,对树突细胞和巨细胞具有抗炎作用.
- 对ALX在特定免疫细胞上的抗炎机制的进一步研究可能为IBD提供新的治疗策略.
更多相关视频
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
130
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
130
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
01:29Inflammatory Bowel Disease IV: Pharmacological Management
118
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
118
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
120
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
120
01:17Drugs for Treatment of Diarrhea-Predominant IBS
153
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
153
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
98
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
98